The Competitive Effects of Performance-Enhancing Drugs: MLB in the Posttesting Era

Scott Brave and Kevin A. Roberts

Journal of Sports Economics, 2019, vol. 20, issue 6, 747-781

Abstract: Using estimates of Major League Baseball (MLB) financials from Forbes , we conduct a cost–benefit analysis of performance-enhancing drug (PED) testing. Player PED suspensions are shown to have lowered franchise values by statistically and economically significant margins through negative impacts on teams’ nongate revenues and expected future profit growth. Testing, however, also increased competitive balance through reductions in player costs which compressed the distribution of team wins per dollar. Finally, we estimate the number of PED suspensions per season which balances the costs and benefits of testing at the league and team levels and compare it to MLB’s current policy.

Keywords: Major League Baseball; performance-enhancing drugs; competitive balance (search for similar items in EconPapers)
Date: 2019
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://journals.sagepub.com/doi/10.1177/1527002518817584 (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:sae:jospec:v:20:y:2019:i:6:p:747-781

DOI: 10.1177/1527002518817584

Access Statistics for this article

More articles in Journal of Sports Economics
Bibliographic data for series maintained by SAGE Publications ().